中国药房2017，Vol.28Issue(17)：2377-2380,4.DOI:10.6039/j.issn.1001-0408.2017.17.20
苁蓉益肾颗粒联合盐酸多奈哌齐片治疗帕金森病痴呆的临床研究
Clinical Study on Congrong Yishen Granules Combined with Donepezil Hydrochloride Tablets in the Treat-ment of Parkinson Disease with Dementia
摘要
Abstract
OBJECTIVE:To observe the effects and safety of Congrong yishen granule combined with Donepezil hydrochloride tablet on mental state and quality of life in patients with Parkinson disease with dementia(PDD). METHODS:A total of 60 PDD patients were randomized into control group and treatment group,with 30 cases in each group. Both groups were given drugs for Parkinson disease. Control group was additionally given Donepezil hydrochloride tablet 5 mg,qd;treatment group was additionally given Congrong yishen granules 2 g,bid,on the basis of control group. The treatment lasted for 6 months in both groups. MMSE, MoCA,ADAS-Cog,ADL-R and TCM symptom score were observed in 2 groups before and after treatment. The occurrence of ADR were compared between 2 groups. RESULTS:Before treatment,there was no statistical significance in MMSE,MoCA, ADAS-Cog,ADL-R or TCM symptom score between 2 groups (P>0.05). After treatment,MMSE and MoCA score of 2 groups were increased significantly,while ADAS-Cog,ADL-R and TCM symptom score were decreased significantly;the treatment group were better than the control group,with statistical significance (P<0.05). No obvious ADR was found in 2 groups. CONCLU-SIONS:Congrong yishen granule combined with donepezil hydrochloride tablet can significantly improve mental state and cogni-tive ability of PDD patients,and relieve clinical symptoms with good safety.关键词
帕金森病痴呆/苁蓉益肾颗粒/精神状态/认知能力/盐酸多奈哌齐片Key words
Parkinson disease with dementia/Congrong yishen granule/Mental state/Cognitive ability/Donepezil hydrochlo-ride tablet分类
医药卫生引用本文复制引用
顾超,沈婷,袁灿兴,安红梅,顾婷婷,张田丽..苁蓉益肾颗粒联合盐酸多奈哌齐片治疗帕金森病痴呆的临床研究[J].中国药房,2017,28(17):2377-2380,4.基金项目
上海市卫生和计划生育委员会科研课题(No.201540184) （No.201540184）
上海市科学技术委员会科研计划项目(No.16401931400) （No.16401931400）
上海市进一步加快中医药事业发展三年行动计划建设项目(No. ZY3-CCCX-2-1002) （No. ZY3-CCCX-2-1002）
上海市"浦东新区院内制剂和经验方规范化临床验证"项目(No.PDYNZJ2015-19) （No.PDYNZJ2015-19）
